Aroxxen not checked
Research Institute of Geroprotective Technologies
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Aroxxen® is an investigational medicinal product administered by inhalation during and after elective percutaneous coronary intervention in accordance with the study protocol.”In the company’s words, NCT07397351 on ClinicalTrials.gov
- Tested for
- Coronary Artery Disease
- Main trialPhase 2
- “This is an open-label, randomized, multicenter Phase II clinical study designed to evaluate the cardioprotective effect, to determine the optimal dosages and duration of inhalation, and to assess the clinical safety of the medicinal product Aroxxen® in patients undergoing elective percutaneous coronary intervention (PCI) with stent implantation. Patients who undergo elective PCI are at risk of myocardial injury associated with the procedure. The study aims to assess whether inhalation of Aroxxen®, administered during the procedure and after it, can reduce markers of myocardial damage and…”In the company’s words, NCT07397351 on ClinicalTrials.gov
Other drugs for Coronary Artery Disease
- XTR004Sinotau Pharmaceutical Group · Phase 3
- EA-230EBI Anti Sepsis BV · Phase 3
- ObicetrapibNewAmsterdam Pharma · Phase 3
- Bempedoic acid/ezetimibeDaiichi Sankyo · Phase 3
- ZiltivekimabNovo Nordisk · Phase 3
- RetatrutideEli Lilly · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 1 Oct 2026 | Aroxxen® Inhalation for Cardioprotection After Elective PCI With Stent Implantation |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026